MY156691A - 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1 - Google Patents

2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1

Info

Publication number
MY156691A
MY156691A MYPI2010001318A MYPI20101318A MY156691A MY 156691 A MY156691 A MY 156691A MY PI2010001318 A MYPI2010001318 A MY PI2010001318A MY PI20101318 A MYPI20101318 A MY PI20101318A MY 156691 A MY156691 A MY 156691A
Authority
MY
Malaysia
Prior art keywords
methylpyrrolidin
benzimidazole
carboxamide crystalline
carboxamide
crystalline
Prior art date
Application number
MYPI2010001318A
Other languages
English (en)
Inventor
Kolaczkowski Lawrence
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY156691(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of MY156691A publication Critical patent/MY156691A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2010001318A 2007-10-12 2008-10-10 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1 MY156691A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
MY156691A true MY156691A (en) 2016-03-15

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010001318A MY156691A (en) 2007-10-12 2008-10-10 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20100090769A (enExample)
CN (2) CN101821270A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Also Published As

Publication number Publication date
CN105367554A (zh) 2016-03-02
DK2722046T3 (en) 2017-03-20
BRPI0816221A8 (pt) 2015-09-22
PT2722046T (pt) 2017-03-15
CR11368A (es) 2010-10-25
NZ583209A (en) 2012-06-29
US20150148392A1 (en) 2015-05-28
AU2008310781B2 (en) 2013-03-28
GT201000080A (es) 2012-04-03
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
CO6280493A2 (es) 2011-05-20
CA3006332A1 (en) 2009-04-16
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2011500589A (ja) 2011-01-06
US8372987B2 (en) 2013-02-12
PL2722046T3 (pl) 2017-06-30
MX2010003772A (es) 2010-04-21
ZA201002090B (en) 2011-11-30
SG185297A1 (en) 2012-11-29
AU2008310781A1 (en) 2009-04-16
MX350019B (es) 2016-12-09
EP2722046A1 (en) 2014-04-23
ECSP10010150A (es) 2010-06-29
CA2696424C (en) 2018-07-10
RU2476434C2 (ru) 2013-02-27
EP2722046B1 (en) 2016-12-21
PA8798401A1 (es) 2009-05-15
US8835647B2 (en) 2014-09-16
US20140024838A1 (en) 2014-01-23
KR20100090769A (ko) 2010-08-17
KR20160039312A (ko) 2016-04-08
US20130123317A1 (en) 2013-05-16
JP2017071618A (ja) 2017-04-13
UA113277C2 (xx) 2017-01-10
CA2696424A1 (en) 2009-04-16
TWI422588B (zh) 2014-01-11
UA101961C2 (xx) 2013-05-27
CN101821270A (zh) 2010-09-01
US9580410B2 (en) 2017-02-28
JP2019001811A (ja) 2019-01-10
ES2620299T3 (es) 2017-06-28
JP2014237659A (ja) 2014-12-18
DOP2010000099A (es) 2017-04-30
BRPI0816221A2 (pt) 2015-06-16
RU2010116397A (ru) 2011-11-20
WO2009049111A1 (en) 2009-04-16
RU2012147692A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2009008510A (es) Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
IL232619A0 (en) Preparations suitable for the treatment of diseases of the spine and related disorders and conditions
SI2150530T1 (sl) Substituirani sulfonamidni derivati
PH12012500620A1 (en) Compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
DE602008000403D1 (de) Behandlung von medizinischen Implantaten, die kalkbeständig sind
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer